Jose Baselga

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Clin Oncol 30:1484-91. 2012
  2. doi Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Lancet 379:633-40. 2012
  3. doi Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    Jose Baselga
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:520-9. 2012
  4. pmc Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
    Gloria Fuentes
    Bioinformatics Institute, A STAR, Singapore
    Breast Cancer Res 13:R54. 2011
  5. doi Treatment of HER2-overexpressing breast cancer
    J Baselga
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Ann Oncol 21:vii36-40. 2010
  6. doi Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 16:12-9. 2011
  7. doi Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Johanna C Bendell
    Sarah Cannon Research Institute, Nashville, TN, USA
    J Clin Oncol 30:282-90. 2012
  8. doi Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:109-19. 2012
  9. doi Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
    Otto Metzger-Filho
    Dana Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 31:1954-60. 2013
  10. doi Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 18:6364-72. 2012

Collaborators

Detail Information

Publications19

  1. doi Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Clin Oncol 30:1484-91. 2012
    ..A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer...
  2. doi Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Lancet 379:633-40. 2012
    ..We argue that the two anti-HER2 agents given together would be better than single-agent therapy...
  3. doi Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    Jose Baselga
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:520-9. 2012
    ..In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity...
  4. pmc Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
    Gloria Fuentes
    Bioinformatics Institute, A STAR, Singapore
    Breast Cancer Res 13:R54. 2011
    ..It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are given in combination...
  5. doi Treatment of HER2-overexpressing breast cancer
    J Baselga
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Ann Oncol 21:vii36-40. 2010
    ..There will also be an increasing tendency towards moving the study of these agents to earlier stages of the disease, namely in the adjuvant and neoadjuvant setting...
  6. doi Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 16:12-9. 2011
    ..This article reviews current data related to the PI3K pathway, its role in breast cancer, the frequency with which PI3K is aberrant in breast cancer, and the potential clinical implications of using agents that target the PI3K pathway...
  7. doi Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Johanna C Bendell
    Sarah Cannon Research Institute, Nashville, TN, USA
    J Clin Oncol 30:282-90. 2012
    ..This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific oral pan-Class I PI3K inhibitor...
  8. doi Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:109-19. 2012
    ....
  9. doi Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
    Otto Metzger-Filho
    Dana Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 31:1954-60. 2013
    ..To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial...
  10. doi Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 18:6364-72. 2012
    ..A nonlinear model (Emax model) was used to describe the relationship between AEE788 exposure and target-pathway modulation in skin and tumor tissues...
  11. doi Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer
    Javier Cortes
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 30:1594-600. 2012
    ..We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy...
  12. pmc Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
    Ashish Juvekar
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Cancer Discov 2:1048-63. 2012
    ....
  13. pmc Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
    Otto Metzger-Filho
    Division of Women s Cancers, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey Building 1238, Boston, MA 02215, USA
    Oncologist 18:134-40. 2013
    ..This study measured the time taken for setting up the different facets of adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO), an nternational phase III study being conducted in 44 participating countries...
  14. pmc Targeted therapies for breast cancer
    Michaela J Higgins
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Clin Invest 121:3797-803. 2011
    ..In addition, combinatorial approaches that act on the secondary mutations and/or compensatory pathways in resistant tumors may markedly improve on the effects of targeted agents used alone...
  15. doi Whole-genome sequencing and cancer therapy: is too much ever enough?
    Levi A Garraway
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer Discov 2:766-8. 2012
    ..This finding highlights the growing debate surrounding the optimal deployment of powerful new genomics technologies in the clinical oncology arena...
  16. doi Breast cancer in 2010: Novel targets and therapies for a personalized approach
    Michaela J Higgins
    Massachusetts General Hospital Cancer Center, 55 Fruit Street, Laurence House, Boston, MA 02114, USA
    Nat Rev Clin Oncol 8:65-6. 2011
    ..Studies with novel targeted agents in defined breast cancer subgroups have revealed exciting developments and highlight the importance of patient selection...
  17. doi The evolving war on cancer
    Daniel A Haber
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Cell 145:19-24. 2011
    ..Could this mark a turning point in the "War on Cancer"?..
  18. pmc Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
    Arkaitz Carracedo
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cell Cycle 7:3805-9. 2008
    ..In this extra-view, we integrate our findings into the mTORC1 signaling network and discuss its relevance for the design of combinatorial therapies with mTORC1 inhibitors...
  19. doi Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
    Maurizio Scaltriti
    Medical Oncology Department, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Mol Cancer Ther 10:817-24. 2011
    ..IPI-504-mediated Hsp90 inhibition may represent a novel therapeutic approach in trastuzumab refractory HER2-positive breast cancer...